C-reactive protein levels and risk of stroke and its subtype in Japanese: The Circulatory Risk in Communities Study (CIRCS)

Atherosclerosis

Volumn 217, Issue 1, 2011, Pages 187-193

  Chei, Choy Lye ^a   Yamagishi, Kazumasa ^a,b   Kitamura, Akihiko ^b   Kiyama, Masahiko ^b   Imano, Hironori ^c   Ohira, Tetsuya ^c   Cui, Renzhe ^c   Tanigawa, Takeshi ^d   Sankai, Tomoko ^e   Ishikawa, Yoshinori ^b   Sato, Shinichi ^b,f   Iso, Hiroyasu ^c  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f CHIBA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

Hs CRP; Japanese; Nested case control study; Stroke

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BODY MASS; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STROKE;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; ISCHEMIA; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDIES; RISK; SMOKING; STROKE;

EID: 79960232608     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.03.001     Document Type: Article

References (32)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Libby P., Ridker P.M. Inflammation atherothrombosis. J Am Coll Cardiol 2006, 48(9 Suppl. A):A33-A46.
3. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
4. Pearson T.A., Mensha G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Center for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
5. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
6. Blake G.J., Ridker P.M. Inflammatory bio-markers cardiovascular risk prediction. Journal of Internal Medicine 2002, 252:283-294.
7. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
8. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
9. Folsom A.R., Aleksic N., Catellier D., et al. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk IN Communities (ARIC) study. Am Heart J 2002, 144:233-238.
10. Everett B.M., Kurth T., Buring J.E., Ridker P.M. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J Am Coll Cardiol 2006, 48:2235-2242.
11. Rost N.S., Wolf P.A., Kase C.S., et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001, 32:2575-2579.
12. Feigin V.L., Laws C.M.M., Bennett D.A., Anderson C.S. Stroke epidemiology: review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurology 2003, 2:43-53.
13. Makita S., Nakamura M., Satoh K., et al. Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population. Atherosclerosis 2009, 204:234-238.
14. Ichihara K., Itoh Y., Min W.K., et al. Diagnostic and epidemiology implications of regional differences in serum concentrations of proteins observed in six Asian cities. Clin Chem Lab Med 2004, 42:800-809.
15. Saito I., Sato S., Nakamura M., et al. A low level of C-reactive protein in Japanese adults and its association with cardiovascular risk factors: the Japan NCVC-Collaborative Inflammation Cohort (JNIC) Study. Atherosclerosis 2007, 194:238-244.
16. Yamada S., Gotoh T., Nakashima Y., et al. Distribution of serum-C-reactive protein and its association with atherosclerotic risk factors in a Japanese population. Am J Epidemiol 2001, 153:1183-1190.
17. Iso H., Cui R., Date C., Kikuchi S., Tamakoshi A C-reactive protein levels and risk of mortality from cardiovascular disease in Japanese: the JACC Study. Atherosclerosis 2009, 207:291-297. JACC Study group.
18. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998, 279:1477-1482.
19. Kuo H.K., Yen C.J., Chang C.H., et al. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005, 4:371-380.
20. Wakugawa Y., Kiyohara Y., Tanizaki Y., et al. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke 2006, 37:27-32.
21. Ohira T. Psychological distress and cardiovascular disease: the Circulatory Risk in Communities Study (CIRCS). J Epidemiol 2010, 20:185-191.
22. Walker A.E., Robins M., Weinfeld F.D. The national survey of stroke. Clinical findings. Stroke 1981, 12(Suppl. 1):I13-I44.
23. Iso H., Rexrode K., Hennekens C.H., Manson J.E. Application of computer tomography-oriented criteria for stroke subtype classification in a prospective study. Ann Epidemiol 2000, 10:81-87.
24. Anderson C.S., Jamrozik K.D., Burvill P.W., et al. Determining the incidence of different subtypes of stroke: results from the Perth Community Stroke Study, 1989-1990. Med J Aust 1993, 158:85-89.
25. WHO technical report series, no. 628; 1978 (arterial hypertension: report of a WHO Expert Committee).
26. Ridler P.M. High sensitivity C-protein inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004, 148:S19-26.
27. Zwaka T.P., Hombach V., Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001, 103:1194-1197.
28. Verma S., Wang C.H., Li S.H., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913-919.
29. Hattori Y., Matsumura M., Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003, 58:186-195.
30. Sato S., Iso H., Noda H., et al. Plasma fibrinogen concentrations and risk of stroke and its subtypes among Japanese men and women. Stroke 2006, 37:2488-2492.
31. Kaptoge S., Di Angelantonio E., Lowe G., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140.
32. Nilsson T.K., Boman K., Jansson J.H., et al. Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (stabilyte) stored at -70°C for 8-11years. Thromb Res 2005, 116:249-254.